Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand

Brooks, Jonathon; Montgomery, Anna; Dalbeth, Nicola; Sapsford, Mark; Kee, Rachel Ngan; Cooper, Amy; Quincey, Vicki; Bhana, Suleman; Gore-Massy, Monique; Hausmann, J.; Liew, Jean W; Machado, Pedro; Sufka, Paul; Sirotich, Emily; Robinson, Philip C; Wallace, Zachary S; Yazdany, Jinoos; Grainger, Rebecca

doi:10.1016/j.lanwpc.2023.100843

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No difference in comorbidity prevalence among these two groups of patients (treated with rituximab vs. those treated with other therapies) was identified. Previous studies showed that there was an increased risk of severe outcomes among patients with underlying rheumatological conditions presenting with COVID-19 and CAD and being treated with rituximab [9,11,32,33]. Hence, a confounding effect of immunosuppression that could have resulted from these primary autoimmune rheumatological conditions could have erroneously attributed the increased risk of severe outcomes to rituximab therapy.…”

Section: Discussionmentioning

confidence: 99%

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

Musuuza,

Kumar,

Posa

et al. 2024

J Clin Med Res

View full text Add to dashboard Cite

Background Reports suggest that patients with both acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and cold agglutinin disease (CAD) may experience poorer survival when treated with rituximab. We conducted a scoping review to evaluate severe outcomes, including intensive care unit (ICU) admission and mortality, in coronavirus disease 2019 (COVID-19) patients with CAD on various treatments, including rituximab. Methods This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Four literature databases were searched on December 19, 2023, for studies reporting lab-confirmed SARS-CoV-2 and CAD, excluding rheumatological conditions. Results Of the 741 screened articles, 19 were included. Studies, predominantly case reports (17/19) or case series (2/19), were mainly from the USA (8/19) and India (3/19), with others across Europe and Asia. Among 23 patients (61% female, median age 61 years), 21/23 had a new CAD diagnosis; only two had pre-existing CAD. Overall, 74% recovered, 21% died, and outcomes for one were unreported. Nine (39%) were ICU-admitted. Of rituximab-treated patients (n = 4), 25% were ICU-admitted, none died. Non-rituximab treatments (n = 19) saw 42% ICU admissions and 26% mortality. Conclusions This review found no increased risk of severe outcomes in CAD and COVID-19 patients treated with rituximab.

show abstract

Section: Discussionmentioning

confidence: 99%

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

Musuuza,

Kumar,

Posa

et al. 2024

J Clin Med Res

View full text Add to dashboard Cite

show abstract

Update zu COVID-19 und Impfungen gegen respiratorische Erreger bei entzündlich-rheumatischen Erkrankungen

Hasseli-Fräbel

2024

Arthritis und Rheuma

View full text Add to dashboard Cite

ZUSAMMENFASSUNGDerzeit steigen die Zahlen der Atemwegserkrankungen in der Wintersaison wieder deutlich an. Trotz des Endes der Pandemie spielt COVID-19 (Coronavirus-Infektion 2019) weiterhin eine wichtige Rolle. Vor allem Menschen ab dem 60. Lebensjahr haben weiterhin ein erhöhtes Risiko, einen schweren COVID-19-Verlauf zu entwickeln. Etwa 33 % der COVID-19-Fälle mussten seit der 40. Kalenderwoche 2023 stationär behandelt werden. Basierend auf der Entwicklung der SARS-CoV-2-Infektion und der Virusvarianten wird seit Januar 2024 eine jährliche Auffrischimpfung gegen COVID-19 mit den adaptierten Impfstoffen für Personen mit entsprechendem Risikoprofil empfohlen. Darüber hinaus soll erneut auf die Anwendung von Schutzmaßnahmen insbesondere in der Wintersaison zur Reduzierung des Infektionsrisikos hingewiesen werden. Für die antivirale Therapie stehen bei erhöhtem Risiko für schwere COVID-19-Verläufe Nirmatrelvir/Ritonavir und Remdesivir zur Verfügung. Neben COVID-19 spielen Influenza-, Pneumokokken- und Respiratory-Syncytial-Virus-Infektionen eine wichtige Rolle. Auch hier kann eine Impfprävention schwere Infektionsverläufe verhindern.

show abstract

Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study

Ma,

Wei,

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

ObjectivesThe impact of rheumatic diseases, long‐term medication, and vaccination on COVID‐19 severity remain insufficiently understood, hindering effective patient management. This study aims to investigate factors influencing COVID‐19 severity in Chinese rheumatic patients and to provide real‐world evidence for patient care.MethodsWe conducted a retrospective observational study consisting of two cohorts, followed by a nested case–control analysis. The outpatient cohort included non‐severe COVID‐19 patients, while the inpatient cohort included consecutive severe COVID‐19 inpatients. Additionally, rheumatic patients from both cohorts were included for the nested case–control study. Clinical information was obtained from electronic medical records and surveys.ResultsA total of 749 outpatients and 167 inpatients were enrolled. In the outpatient cohort, rheumatic diseases were identified as a risk factor for the severity of dyspnea (No rheumatic disease: OR = 0.577, 95% CI = 0.396–0.841, p = .004), but not for mortality, length of hospitalization, or hospitalization costs in the inpatient cohort. Long‐term glucocorticoids use was identified as an independent risk factor for severity of dyspnea in rheumatic patients (OR = 1.814, 95% CI = 1.235–2.663, p = .002), while vaccination and immunosuppressant treatment showed no association. Vaccination was identified as a protective factor against hospitalization due to COVID‐19 in patients with rheumatic diseases (OR = 0.031, 95% CI = 0.007–0.136, p < .001), whereas long‐term glucocorticoids and immunosuppressant treatment showed no association.ConclusionsRheumatic diseases and long‐term glucocorticoids use are significant risk factors for COVID‐19 severity in the Chinese population, whereas emphasizing the protective effects of vaccines against COVID‐19 severity is crucial. Additionally, the investigation provides preliminary support for the concept that long‐term immunosuppressant therapy does not necessarily require additional prescription adjustments.

show abstract

Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand

Cited by 4 publications

References 24 publications

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

Update zu COVID-19 und Impfungen gegen respiratorische Erreger bei entzündlich-rheumatischen Erkrankungen

Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study

Contact Info

Product

Resources

About